Location

NeuroCores, Inc.
201 Washington Street,
#2600. Boston,
MA 02108
info@neurocores.com

News

Milestone Highlights

#
$
2005

Plasmalogen research starts

2006

Successful development of extracting plasmalogen from chicken breast

2007

Succeeded in improving and simplifying plasmalogen detection method

2009

Clinical studies with natural Plasmalogen in Alzheimer's disease (AD) patients started

2012

Plasmalogen Research in AD patients published

2013

Research started to seek to extract better plasmalogen using scallops

2014

A large-scale clinical trial started with mild AD patients

2015

Development of plasmalogen derivatives started

2016

Elucidating plasmalogen activates Akt and ERK by binding several orphan GCPRs

2020

Completion of KIT-13 development, the lead asset for future NeuroCores, Inc.

2021

KIT-13 research on Rett syndrome started

2023

KIT-13 (Rett Syndrome): US FDA-RPDD (Rare Pediatric Drug Designation) and ODD (Orphan Drug Designation) granted

NeuroCores incorporated

KIT-13 Nonclinical Studies initiated

2024

KIT-20 (Leigh Syndrome): US FDA-RPDD (Rare Pediatric Drug Designation) and ODD (Orphan Drug Designation) granted

2025

KIT-13 IND Submission to US FDA

KIT-13 Phase 1 clinical study to start

Our achievements

Rare Pediatric Designation

March 2023 –  our lead asset KIT-13 was granted Rare Pediatric Disease Designation (RPDD) for the treatment of Rett Syndrome.

September 2024 – our 2nd pipeline asset KIT-20 was granted RPDD for treatment of Leigh Syndrome

Orphan Drug Designation

March 2023 – our lead asset KIT-13 was granted Orphan Drug Desigmation (ODD) for the treatment of Rett Syndrome.

October 2024 – our 2nd pipeline asset KIT-20 was granted ODD for the treatment of Leigh Syndrome

A new company incorporated

In April 2023, NeuroCores is incorporated in the United States, as a subsidiary of the prestigious research institution, the Institute of Rheological Functions of Food (Fukuoka, Japan).

The company is based in Boston, Massachusetts.

Publications

Research

Biological Functions of Plasmologen


Plasmalogens (Pls) are one kind of phospholipids enriched in the brain and other organs. These lipids were thought to be involved in the membrane bilayer formation and anti-oxidant function.

However, extensive studies reveal that Pls exhibits various beneficial biological activities including prevention of neuroinflammation, improvement of cognitive function, and inhibition of neuronal cell death.

Plasmalogens Rescue Neuronal Cell Death through an Activation of AKT and ERK Survival Signaling


Neuronal cells are susceptible to many stresses, which will cause the apoptosis and neurodegenerative diseases.
The precise molecular mechanism behind the neuronal protection against these apoptotic stimuli is necessary for drug discovery. In the present study, we have found that plasmalogens (Pls), which are glycerophospholipids containing vinyl ether linkage at sn-1 position, can protect the neuronal cell death upon serum deprivation.

Plasmalogens, the Vinyl Ether-Linked Glycerophospholipids, Enhance Learning and Memory by Regulating Brain-Derived Neurotrophic Factor


Plasmalogens (Pls), a kind of glycerophospholipids, have shown potent biological effects but their role in hippocampus-dependent memory remained mostly elusive. Here, we first report Pls can enhance endogenous expression of brain-derived neurotrophic factor (Bdnf) in the hippocampus and promotes neurogenesis associated with improvement of learning and memory in mice.